ASLAN Pharmaceuticals (ASLN) Competitors $0.60 0.00 (0.00%) As of 08/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock ASLN vs. ONCO, CDT, CPHI, OGEN, REVB, GLTO, INM, SPRB, EVAX, and XBIOShould you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Onconetix (ONCO), CDT Equity (CDT), China Pharma (CPHI), Oragenics (OGEN), Revelation Biosciences (REVB), Galecto (GLTO), InMed Pharmaceuticals (INM), Spruce Biosciences (SPRB), Evaxion A/S (EVAX), and Xenetic Biosciences (XBIO). These companies are all part of the "pharmaceutical products" industry. ASLAN Pharmaceuticals vs. Its Competitors Onconetix CDT Equity China Pharma Oragenics Revelation Biosciences Galecto InMed Pharmaceuticals Spruce Biosciences Evaxion A/S Xenetic Biosciences Onconetix (NASDAQ:ONCO) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation. Does the media favor ONCO or ASLN? In the previous week, Onconetix had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for ASLAN Pharmaceuticals. Onconetix's average media sentiment score of 1.88 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Onconetix is being referred to more favorably in the media. Company Overall Sentiment Onconetix Very Positive ASLAN Pharmaceuticals Neutral Is ONCO or ASLN more profitable? ASLAN Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Onconetix's return on equity of -192.74% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Onconetix-3,327.03% -192.74% -89.55% ASLAN Pharmaceuticals N/A -8,454.87%-121.60% Which has more risk and volatility, ONCO or ASLN? Onconetix has a beta of 3.37, suggesting that its share price is 237% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ONCO or ASLN? 23.9% of Onconetix shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 3.1% of Onconetix shares are held by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings & valuation, ONCO or ASLN? ASLAN Pharmaceuticals has higher revenue and earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnconetix$2.52M1.81-$58.69MN/AN/AASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03 SummaryOnconetix beats ASLAN Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASLN vs. The Competition Export to ExcelMetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$853.28M$5.74B$9.78BDividend YieldN/A4.84%4.40%4.04%P/E Ratio-0.031.1630.8326.39Price / Sales0.10138.93382.9086.63Price / CashN/A19.5637.7259.11Price / Book-0.096.7710.106.62Net Income-$44.22M-$4.20M$3.26B$265.42M7 Day PerformanceN/A11.77%3.90%3.58%1 Month PerformanceN/A3.47%3.73%0.46%1 Year PerformanceN/A15.88%37.68%19.41% ASLAN Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330ONCOOnconetix1.1012 of 5 stars$3.12+3.3%N/A-99.4%$4.83M$2.52M0.0012CDTCDT Equity0.2187 of 5 stars$1.54-11.3%N/A-99.4%$4.70MN/A0.003News CoverageGap DownHigh Trading VolumeCPHIChina PharmaN/A$1.42flatN/A-93.6%$4.63M$4.40M0.00250News CoverageOGENOragenics0.1412 of 5 stars$1.11-0.9%N/A-96.3%$4.58MN/A-0.165REVBRevelation Biosciences0.2439 of 5 stars$2.66-6.7%N/A-95.2%$4.52MN/A-0.0410News CoverageGLTOGalecto3.7684 of 5 stars$3.41+0.1%$10.00+193.7%-75.6%$4.51MN/A-0.2640INMInMed Pharmaceuticals1.4205 of 5 stars$2.26+1.1%N/A-70.4%$4.50M$4.92M-0.1910SPRBSpruce Biosciences1.6897 of 5 stars$7.95-3.0%$131.25+1,550.9%-78.4%$4.47M$4.91M-8.4620EVAXEvaxion A/S2.5108 of 5 stars$3.15-2.0%$10.00+218.0%-79.8%$4.41M$3.18M-2.3860XBIOXenetic Biosciences1.361 of 5 stars$2.87+0.2%N/A-31.3%$4.41M$2.50M-1.434 Related Companies and Tools Related Companies ONCO Alternatives CDT Alternatives CPHI Alternatives OGEN Alternatives REVB Alternatives GLTO Alternatives INM Alternatives SPRB Alternatives EVAX Alternatives XBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASLN) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access